Tags : Royalty Pharma

Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

Shots: PTC Therapeutics to receive $650M as upfront in cash in exchange for ~43% of the risdiplam royalties, up to a specified amount while PTC maintains the majority of the risdiplam royalty stream and retains all economics associated with up to ~$400M in remaining regulatory and commercial milestones The collaboration enables PTC to further develop […]Read More

Eisai to Transfer Royalty Rights for Tazemetostat to Royalty Pharma

Shots: Eisai to receive $110M upfront and $220M on marketing approval for tazemetostat in the US for certain indications and Royalty Pharma to get rights to receive royalties from Epizyme on sales outside of Japan In 2015, Epizyme and Eisai made amendment in their agreement for Tazemetostat candidate where Eisai will develop and commercialize in […]Read More